These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 28762251)

  • 1. Helicobacter pylori management in ASEAN: The Bangkok consensus report.
    Mahachai V; Vilaichone RK; Pittayanon R; Rojborwonwitaya J; Leelakusolvong S; Maneerattanaporn M; Chotivitayatarakorn P; Treeprasertsuk S; Kositchaiwat C; Pisespongsa P; Mairiang P; Rani A; Leow A; Mya SM; Lee YC; Vannarath S; Rasachak B; Chakravuth O; Aung MM; Ang TL; Sollano JD; Trong Quach D; Sansak I; Wiwattanachang O; Harnsomburana P; Syam AF; Yamaoka Y; Fock KM; Goh KL; Sugano K; Graham D
    J Gastroenterol Hepatol; 2018 Jan; 33(1):37-56. PubMed ID: 28762251
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Toronto Consensus for the Treatment of Helicobacter pylori Infection in Adults.
    Fallone CA; Chiba N; van Zanten SV; Fischbach L; Gisbert JP; Hunt RH; Jones NL; Render C; Leontiadis GI; Moayyedi P; Marshall JK
    Gastroenterology; 2016 Jul; 151(1):51-69.e14. PubMed ID: 27102658
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacological effects of metronidazole+tetracycline+bismuth subcitrate versus omeprazole+amoxycillin+bismuth subcitrate in Helicobacter pylori-related gastritis and peptic ulcer disease.
    Park KN; Hahm JS; Kim HJ
    Eur J Gastroenterol Hepatol; 1994 Dec; 6 Suppl 1():S103-7. PubMed ID: 7735924
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sitafloxacin-based third-line rescue regimens for Helicobacter pylori infection in Japan.
    Furuta T; Sugimoto M; Kodaira C; Nishino M; Yamade M; Uotani T; Sahara S; Ichikawa H; Yamada T; Osawa S; Sugimoto K; Watanabe H; Umemura K
    J Gastroenterol Hepatol; 2014 Mar; 29(3):487-93. PubMed ID: 24224808
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neither 10- nor 14-Day Sequential Treatment is better than Standard Triple Therapy for Helicobacter Pylori Eradication.
    Warrington E; López-Román O; Tirado Montijo R; Urbina R; Cruz-Correa M; Toro DH
    P R Health Sci J; 2016 Dec; 35(4):203-208. PubMed ID: 27898166
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Expanded indication of National Health Insurance for H. pylori associated gastritis].
    Kato M
    Nihon Rinsho; 2014 May; 72(5):967-76. PubMed ID: 24912302
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Concomitant and hybrid therapy for Helicobacter pylori infection: A randomized clinical trial.
    Heo J; Jeon SW; Jung JT; Kwon JG; Lee DW; Kim HS; Yang CH; Park JB; Park KS; Cho KB; Lee SH; Jang BI;
    J Gastroenterol Hepatol; 2015 Sep; 30(9):1361-6. PubMed ID: 25867608
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevalence and Pattern of Antibiotic Resistant Strains of Helicobacter Pylori Infection in ASEAN.
    Vilaichone RK; Quach DT; Yamaoka Y; Sugano K; Mahachai V
    Asian Pac J Cancer Prev; 2018 May; 19(5):1411-1413. PubMed ID: 29802708
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Eradication of Helicobacter pylori in peptic ulcer and chronic gastritis. A randomized clinical trial].
    Rodríguez Hernández H; Sánchez Anguiano LF; Quiñones E
    Rev Gastroenterol Mex; 1998; 63(1):21-7. PubMed ID: 10068745
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Concomitant, bismuth quadruple, and 14-day triple therapy in the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial.
    Liou JM; Fang YJ; Chen CC; Bair MJ; Chang CY; Lee YC; Chen MJ; Chen CC; Tseng CH; Hsu YC; Lee JY; Yang TH; Luo JC; Chang CC; Chen CY; Chen PY; Shun CT; Hsu WF; Hu WH; Chen YN; Sheu BS; Lin JT; Wu JY; El-Omar EM; Wu MS;
    Lancet; 2016 Nov; 388(10058):2355-2365. PubMed ID: 27769562
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cumulative H. pylori eradication rates in clinical practice by adopting first and second-line regimens proposed by the Maastricht III consensus and a third-line empirical regimen.
    Rokkas T; Sechopoulos P; Robotis I; Margantinis G; Pistiolas D
    Am J Gastroenterol; 2009 Jan; 104(1):21-5. PubMed ID: 19098844
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel and Effective Therapeutic Regimens for
    Hu Y; Zhu Y; Lu NH
    Front Cell Infect Microbiol; 2017; 7():168. PubMed ID: 28529929
    [No Abstract]   [Full Text] [Related]  

  • 13. Optimized high-dose amoxicillin-proton-pump inhibitor dual therapies fail to achieve high cure rates in China.
    Hu JL; Yang J; Zhou YB; Li P; Han R; Fang DC
    Saudi J Gastroenterol; 2017; 23(5):275-280. PubMed ID: 28937021
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ultimate eradication rate of Helicobacter pylori after first, second, or third-line therapy in Korea.
    Yoon K; Kim N; Nam RH; Suh JH; Lee S; Kim JM; Lee JY; Kwon YH; Choi YJ; Yoon H; Shin CM; Park YS; Lee DH
    J Gastroenterol Hepatol; 2015 Mar; 30(3):490-5. PubMed ID: 25363555
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Management of Helicobacter pylori infection-the Maastricht V/Florence Consensus Report.
    Malfertheiner P; Megraud F; O'Morain CA; Gisbert JP; Kuipers EJ; Axon AT; Bazzoli F; Gasbarrini A; Atherton J; Graham DY; Hunt R; Moayyedi P; Rokkas T; Rugge M; Selgrad M; Suerbaum S; Sugano K; El-Omar EM;
    Gut; 2017 Jan; 66(1):6-30. PubMed ID: 27707777
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Helicobacter pylori-associated diseases].
    Gisbert JP
    Gastroenterol Hepatol; 2015 Sep; 38 Suppl 1():39-48. PubMed ID: 26520195
    [TBL] [Abstract][Full Text] [Related]  

  • 17. IV Spanish Consensus Conference on Helicobacter pylori infection treatment.
    Gisbert JP; Molina-Infante J; Amador J; Bermejo F; Bujanda L; Calvet X; Castro-Fernández M; Cuadrado-Lavín A; Elizalde JI; Gene E; Gomollón F; Lanas Á; Martín de Argila C; Mearin F; Montoro M; Pérez-Aisa Á; Pérez-Trallero E; McNicholl AG
    Gastroenterol Hepatol; 2016 Dec; 39(10):697-721. PubMed ID: 27342080
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of moxifloxacin-based sequential and hybrid therapy for first-line Helicobacter pylori eradication.
    Hwang JJ; Lee DH; Yoon H; Shin CM; Park YS; Kim N
    World J Gastroenterol; 2015 Sep; 21(35):10234-41. PubMed ID: 26401089
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ten-day triple therapy versus sequential therapy versus concomitant therapy as first-line treatment for Helicobacter pylori infection.
    Ang TL; Fock KM; Song M; Ang D; Kwek AB; Ong J; Tan J; Teo EK; Dhamodaran S
    J Gastroenterol Hepatol; 2015 Jul; 30(7):1134-9. PubMed ID: 25639278
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of treatment regimens for the eradication of Helicobacter pylori in duodenal ulcer.
    Vakil N; Fennerty MB
    Am J Gastroenterol; 1996 Feb; 91(2):239-45. PubMed ID: 8607487
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.